Prokarium

Prokarium is a clinical-stage biopharmaceutical company pioneering bacterial immunotherapies for the treatment of solid tumours. The company's proprietary ZH9 bacterial chassis platform is naturally tumor-targeting and oncolytic, designed to overcome the suppressive tumor microenvironment and deliver diverse immunotherapy cargo. Prokarium's lead program, ZH9, is in Phase 1/1b clinical trials for non-muscle invasive bladder cancer (NMIBC) with encouraging interim safety and efficacy results.